Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC68H85F2N11O17P2S2 |
InChIKeySEILIWDWNYTJFI-UOJLPHGUSA-N |
CAS Registry2417370-71-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 17 Feb 2021 |